Nitric Oxide

CHEMBL1200689 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
30.0 g/mol
LogP
0.2
Phase
4

A naturally occurring gas that helps relax and widen blood vessels, given medically to treat dangerously high blood pressure in the lungs of newborns.

Masse moléculaire

30,0060 g/mol

LogP

0,20

TPSA

18,10 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

[N]=O

InChI

InChI=1S/NO/c1-2

Molecular Formula

NO

HBD / HBA

- / 1

Liaisons Rotatives

0

Atomes Lourds

2

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A naturally occurring gas that helps relax and widen blood vessels, given medically to treat dangerously high blood pressure in the lungs of newborns.

Yes, Nitric Oxide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200689. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 145068. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.